Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19 Haidong Dong Editorial 28 April 2020 Pages: 911 - 912
Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma Maria Christina CoxCaterina LapentaStefano M. Santini Review 22 April 2020 Pages: 913 - 925
Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors Qing WuJunjin LiuXianhe Xie Original Article 19 February 2020 Pages: 927 - 936
Correction to: Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors Qing WuJunjin LiuXianhe Xie Correction 11 March 2020 Pages: 937 - 937
Development and characterization of a novel anti-OX40 antibody for potent immune activation Zhihui KuangHua JingJunjian Liu Original Article 20 February 2020 Pages: 939 - 950
miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy Meng ZhangYanmei ShiWeiping Min Original Article 20 February 2020 Pages: 951 - 967
CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies Ashanty M. MeloMelissa J. ConroyDerek G. Doherty Original Article 20 February 2020 Pages: 969 - 982
Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection Ilya TsimafeyeuRustem GafanovKristina Zakurdaeva Original Article 20 February 2020 Pages: 983 - 988
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer Mizuho OharaKenzo OharaHiroya Kobayashi Original Article 21 February 2020 Pages: 989 - 999
Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model Jose-Ignacio Rodriguez-BarbosaMiyuki AzumaMaria-Luisa del Rio Original Article 22 February 2020 Pages: 1001 - 1014
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro Shannon BurkeAmy ShergoldDanielle K. Carroll Original Article Open access 22 February 2020 Pages: 1015 - 1027
Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells Philipp GierlichVeronika LexMatthias Eyrich Original Article Open access 25 February 2020 Pages: 1029 - 1042
Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival Karl-Frederick KarstensJan KempskiSamuel Huber Original Article Open access 25 February 2020 Pages: 1043 - 1056
Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications Yu-Jie ZhouGui-Qi ZhuXiao-Bo Li Original Article 25 February 2020 Pages: 1057 - 1069
Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma Asif A. DarRushikesh S. PatilShubhada V. Chiplunkar Original Article 26 February 2020 Pages: 1071 - 1086
Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma Lata SinghMithalesh Kumar SinghSeema Kashyap Original Article 26 February 2020 Pages: 1087 - 1099
Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy Malgorzata WachowskaJoanna StachuraAngelika Muchowicz Original Article Open access 28 February 2020 Pages: 1101 - 1112
Neutrophils are mediators of metastatic prostate cancer progression in bone Diane L. Costanzo-GarveyTyler KeeleyLeah M. Cook Original Article Open access 29 February 2020 Pages: 1113 - 1130
Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study Eiji KiyoharaAtsushi TanemuraIchiro Katayama Clinical Trial Report 11 February 2020 Pages: 1131 - 1140
Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy Matteo BelloneArianna BreviVincenzo Russo Meeting Report 06 February 2020 Pages: 1141 - 1151
ESTIMATE algorithm is not appropriate for inferring tumor purity and stromal and immune cell admixture in hematopoietic or stromal tumors Qiang LiuYi FangJing Wang Letter to the Editors 09 March 2020 Pages: 1153 - 1154